(0) POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced the publication of the meeting notice for the Annual General Meeting, which will take place in a closed virtual session on June 23
rd, 2021 at 1.00pm CEST.
In the context of the COVID-19 pandemic and in accordance with the regulations introduced to limit or prohibit travel and collective gatherings to prevent the spread of the COVID-19 virus (article 4 of Order n° 2020-321 of March 25, 2020 as amended and extended and decree n° 2020-1310 of October 29, 2020 as amended and extended including by the decree n° 2021-541 of May 1, 2021), Poxel s Board of Directors has decided to hold the 2021 Annual General Meeting behind closed doors, without the physical presence of shareholders. Therefore, the Company strongly encourages its shareholders to use th
Poxel SA: Poxel Announces Participation at Upcoming Virtual Investor Conferences in June POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its participation at upcoming virtual investor conferences in June 2021. Thomas Kuhn, CEO, will present the company and Poxel management team members will be available for one-on-one virtual meetings.
Jefferies Global Healthcare Conference
st from 11:00 am to 11:25 am ET.
JMP Securities Conference
th from 10:30 am to 10:55 am ET.
Raymond James Human Health Innovations Conference
Date: June 21-23
nd from 8:40 am to 9:10 am ET.
印象派大師莫內《睡蓮池》賣出19 6億元 創下系列拍賣記錄 -風傳媒 storm.mg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from storm.mg Daily Mail and Mail on Sunday newspapers.
Poxel SA: Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society
th Annual Meeting of the Japan Diabetes Society (May 20-22, 2021).
Three presentations on Imeglimin will be included in an oral session for large clinical studies in the afternoon (2:30 pm to 3:40 pm JST) of May 20. These presentations will be focused on the analysis and interpretation of clinical data derived from Phase 2 and Phase 3 (TIMES program) trials with Imeglimin, Poxel s novel antidiabetic investigational drug, where Japanese patients with type 2 diabetes (T2DM) were enrolled and studied:
TIMES 2: Long-term Phase 3 study with Imeglimin as a mono- and add-on therapies in Japanese T2DM
Тысячи жителей ЦАР вышли на митинг против антироссийских публикаций в СМИ Франции riafan.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from riafan.ru Daily Mail and Mail on Sunday newspapers.